Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer

被引:17
作者
Nakatani, Yoshihisa [1 ]
Kawakami, Hisato [2 ]
Ichikawa, Masashi [1 ]
Yamamoto, Sachiyo [1 ]
Otsuka, Yasuo [2 ]
Mashiko, Akiko [1 ]
Takashima, Yasutoshi [3 ]
Ito, Akihiko [3 ]
Nakagawa, Kazuhiko [2 ]
Arima, Shuji [1 ]
机构
[1] Kindai Univ, Fac Med, Dept Nephrol, 377-2 Ohno Higashi, Osaka, Osaka 5898511, Japan
[2] Kindai Univ, Fac Med, Dept Clin Oncol, 377-2 Ohno Higashi, Osaka, Osaka 5898511, Japan
[3] Kindai Univ, Fac Med, Dept Pathol, 377-2 Ohno Higashi, Osaka, Osaka 5898511, Japan
关键词
Granulomatous tubulointerstitial nephritis; Nivolumab; Gastric cancer; IMMUNE CHECKPOINT INHIBITORS; TUBULAR EPITHELIAL-CELLS; INTERSTITIAL NEPHRITIS; LUNG-CANCER;
D O I
10.1007/s10637-018-0596-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We here report a case of nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer. A 68-year-old woman with recurrent gastric cancer developed acute kidney injury associated with kidney enlargement and urinary leukocytes after 38 cycles of nivolumab treatment. A diagnosis of acute granulomatous tubulointerstitial nephritis was made based on kidney biopsy findings. Immunohistochemistry revealed expression of programmed cell death-ligand 1 (PD-L1) in degenerated epithelial cells of collecting tubules. Among infiltrating immune cells, aggregation of T cells was more extensive than that of B cells, with CD4(+) T cells outnumbering CD8(+) T cells, consistent with the relative numbers of these cells in the circulation. Treatment with methylprednisolone (1.0 mg/kg daily) led to a rapid improvement in renal function and reduction in the number of circulating CD4(+) T cells. Prompt administration of high-dose corticosteroid is thus recommended after diagnosis of this adverse event of nivolumab treatment by kidney biopsy.
引用
收藏
页码:726 / 731
页数:6
相关论文
共 12 条
  • [1] [Anonymous], J CLIN ONCOLOGY S48
  • [2] Acute interstitial nephritis related to immune checkpoint inhibitors
    Belliere, Julie
    Meyer, Nicolas
    Mazieres, Julien
    Ollier, Sylvie
    Boulinguez, Serge
    Delas, Audrey
    Ribes, David
    Faguer, Stanislas
    [J]. BRITISH JOURNAL OF CANCER, 2016, 115 (12) : 1457 - 1461
  • [3] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [4] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
    Brahmer, Julie R.
    Drake, Charles G.
    Wollner, Ira
    Powderly, John D.
    Picus, Joel
    Sharfman, William H.
    Stankevich, Elizabeth
    Pons, Alice
    Salay, Theresa M.
    McMiller, Tracee L.
    Gilson, Marta M.
    Wang, Changyu
    Selby, Mark
    Taube, Janis M.
    Anders, Robert
    Chen, Lieping
    Korman, Alan J.
    Pardoll, Drew M.
    Lowy, Israel
    Topalian, Suzanne L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) : 3167 - 3175
  • [5] Expression of B7-H1 in inflammatory renal tubular epithelial cells
    Chen, YW
    Zhang, JB
    Li, JY
    Zou, LY
    Zhao, TT
    Tang, Y
    Wu, YZ
    [J]. NEPHRON EXPERIMENTAL NEPHROLOGY, 2006, 102 (3-4): : E81 - E92
  • [6] Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
    Escandon, Julia
    Peacock, Stephanie
    Trabolsi, Asaad
    Thomas, David B.
    Layka, Ayman
    Lutzky, Jose
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [7] Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer
    Haratani, Koji
    Hayashi, Hidetoshi
    Chiba, Yasutaka
    Kudo, Keita
    Yonesaka, Kimio
    Kato, Ryoji
    Kaneda, Hiroyasu
    Hasegawa, Yoshikazu
    Tanaka, Kaoru
    Takeda, Masayuki
    Nakagawa, Kazuhiko
    [J]. JAMA ONCOLOGY, 2018, 4 (03) : 374 - 378
  • [8] Renal effects of immune checkpoint inhibitors
    Izzedine, Hassan
    Mateus, Christine
    Boutros, Celine
    Robert, Caroline
    Rouvier, Philippe
    Amoura, Zahir
    Mathian, Alexis
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (06) : 936 - 942
  • [9] Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
    Kang, Yoon-Koo
    Boku, Narikazu
    Satoh, Taroh
    Ryu, Min-Hee
    Chao, Yee
    Kato, Ken
    Chung, Hyun Cheol
    Chen, Jen-Shi
    Muro, Kei
    Kang, Won Ki
    Yeh, Kun-Huei
    Yoshikawa, Takaki
    Oh, Sang Cheul
    Bai, Li-Yuan
    Tamura, Takao
    Lee, Keun-Wook
    Hamamoto, Yasuo
    Kim, Jong Gwang
    Chin, Keisho
    Oh, Do-Youn
    Minashi, Keiko
    Cho, Jae Yong
    Tsuda, Masahiro
    Chen, Li-Tzong
    [J]. LANCET, 2017, 390 (10111) : 2461 - 2471
  • [10] Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
    Motzer, R. J.
    Escudier, B.
    McDermott, D. F.
    George, S.
    Hammers, H. J.
    Srinivas, S.
    Tykodi, S. S.
    Sosman, J. A.
    Procopio, G.
    Plimack, E. R.
    Castellano, D.
    Choueiri, T. K.
    Gurney, H.
    Donskov, F.
    Bono, P.
    Wagstaff, J.
    Gauler, T. C.
    Ueda, T.
    Tomita, Y.
    Schutz, F. A.
    Kollmannsberger, C.
    Larkin, J.
    Ravaud, A.
    Simon, J. S.
    Xu, L-A
    Waxman, I. M.
    Sharma, P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) : 1803 - 1813